Related Experiment Video

Updated: Jun 3, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Advanced treatments in non-clear renal cell carcinoma

El Mehdi Tazi1, Ismail Essadi, Mohamed Fadl Tazi

  • 1Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco. moulay.elmehdi@yahoo.fr

Urology Journal
|March 16, 2011
PubMed
Abstract

Insights

Targeted therapies show limited options for non-clear cell renal cell carcinoma (RCC) subtypes. Sunitinib is a well-tolerated, effective option for these rare kidney cancers.

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Renal cell carcinoma (RCC) comprises various histologic subtypes beyond clear cell.
  • Non-clear cell RCC subtypes, including papillary I and II, chromophobe, and collecting duct, have distinct molecular profiles.
  • Understanding these unique profiles is crucial for developing effective targeted therapies.

Purpose of the Study:

  • To review targeted therapies for non-clear cell RCC subtypes.
  • To describe the genetic and molecular characteristics of these distinct kidney cancer subtypes.
  • To highlight the integral role of these differences in novel agent development and efficacy.

Main Methods:

  • Literature review of MEDLINE database searches (2000-2010).
  • Assessment of targeted therapy trials in non-clear cell RCC.
  • Discussion of cytoreductive nephrectomy, neoadjuvant, and adjuvant targeted therapy roles.
  • Identification of future research areas.

Main Results:

  • Most clinical trials for targeted therapies have excluded non-clear cell RCC subtypes.
  • This exclusion results in limited therapeutic options for patients and oncologists.
  • Limited data exists on the efficacy of novel agents in these specific RCC subtypes.

Conclusions:

  • Advanced non-clear cell RCC requires thorough metastatic and surgical evaluation, including potential nephrectomy, lymphadenectomy, and metastectomy.
  • Aggressive surgical extirpation is frequently recommended.
  • Sunitinib demonstrates adequate tolerability and oncologic activity in non-clear cell histology.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...